A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

NCT02952989 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped Due to overall benefit/risk profile

Conditions

Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Breast Neoplasms
Urinary Bladder Neoplasm
Carcinoma, Squamous Cell of Head and Neck
Colorectal Neoplasms
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SGN-2FF
DRUG: pembrolizumab

Sponsor

Seagen Inc.